Clinical studies of CS-866, the newest angiotensin II receptor antagonist

American Journal of Cardiology

Volumn 87, Issue 8 SUPPL., 2001, Pages 37-43

  Neutel, Joel M ^a  

^a Orange County Heart Institute and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; OLMESARTAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESSENTIAL HYPERTENSION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; VERTIGO;

EID: 0035912126     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01510-7     Document Type: Article

References (8)

1. Angiotensin II receptor antagonists
2. Angiotensin II and the pathophysiology of cardiovascular remodeling
3. Angiotensin, fibrinolysis, and vascular homeostasis
4. Angiotensin II: New investigational approaches to its role in atherosclerosis, inflammation, and oxidative stress
5. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
6. Drugs of the future: CS-866
7. Newly emerging pharmacologic differences in angiotensin II receptor blockers
8. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure